05/28/2020
In this podcast, Dr Lee discusses available data on the use of remdesivir for the treatment of severe COVID-19, and how the FDA's emergency authorization of remdesivir will impact the care of hospitalized patients with severe COVID-19 as the pandemic progresses.
For more COVID-19 coverage, visit COVID-19 Care360.
References:
- National Institute of Allergy and Infectious Diseases. Adaptive COVID-19 treatment trial (ACTT). https://clinicaltrials.gov/ct2/show/NCT04280705 NCT04280705. Accessed May 14, 2020.
- Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment. News release. US Food and Drug Administration. May 1, 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment
- National Institutes of Health. COVID-19 treatment guidelines. https://covid19treatmentguidelines.nih.gov/introduction/ Site last updated May 12, 2020. Accessed May 14, 2020.
Bruce Y. Lee, MD, MBA, is a professor of Health Policy Management at the City University of New York, and an internationally-recognized expert in infectious disease, epidemic, and pandemic response, prevention, and control.
